Results 91 to 100 of about 33,653 (199)

Expression of c-erbB-2, p53 and c-myc proteins in male breast carcinoma: Comparison with traditional prognostic factors and survival

Brazilian Journal of Medical and Biological Research, 2001
There are few data evaluating biological markers for men with breast cancer. The purpose of the present study was to analyze the expression of the oncogenes c-erbB-2 and c-myc and of the suppressor gene p53 by immunohistochemical techniques in archival ...
M. Mourão Netto, A.F. Logullo, S. Nonogaki, R.R. Brentani, M.M. Brentani   +4 more
doaj   +1 more source

Dacomitinib as a First‐Line Therapy for Advanced EGFR‐Mutated Non‐Small Cell Lung Cancer Without Brain Metastases: A Multicenter Retrospective Observational Study

Cancer Medicine, Volume 15, Issue 3, March 2026.
ABSTRACT Background Real‐world evidence regarding the use of dacomitinib as a first‐line therapy for advanced non‐small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations remains limited. This multicenter, retrospective cohort study aimed to evaluate the clinical outcomes of dacomitinib as a first‐line treatment in patients
Ping‐Chih Hsu, How‐Wen Ko, Li‐Chung Chiu, Shih‐Hao Huang, Chung‐Shu Lee, Yu‐Ching Lin, Scott Chih‐Hsi Kuo, Jia‐Shiuan Ju, Chin‐Chou Wang, Cheng‐Ta Yang   +9 more
wiley   +1 more source

Co-Targeting ErbB Receptors and the PI3K/AKT Axis in Androgen-Independent Taxane-Sensitive and Taxane-Resistant Human Prostate Cancer Cells. [PDF]

Cancers (Basel), 2022
Adediran S, Wang L, Khan MA, Guang W, Fan X, Dan H, Qi J, Jay SM, Carrier F, Hussain A.   +9 more
europepmc   +1 more source

Multi‐omic profiling defines three distinct molecular subtypes of urothelial carcinoma with implications for precision therapy

Clinical and Translational Medicine, Volume 16, Issue 3, March 2026.
We developed three UC clusters, applicable for MIBC and NMIBC, which were validated using transcriptomic- and proteomic datasets. Publically available UC cell lines were assigned to the clusters, to have in vitro models representing each cluster. The clusters differ in molecular and biological signatures, with distinct prognostic and therapeutic ...
Nils C. H. van Creij, Piotr Tymoszuk, Florian Handle, Andreas Seeber, Teresa Sellemond, Agnieszka Martowicz, Eva Comperat, Hamed Wafa, Steffen Ormanns, Michael Günther, Walther Parson, Maxim Noeparast, Frédéric R. Santer, José Daniel Subiela, Petros Grivas, Roger Li, Zoran Culig, Renate Pichler   +17 more
wiley   +1 more source

Non‐HLA Risk Loci ERBB3/IKZF4 and ERBB2/IKZF3/GSDMB/ORMDL3 Interact to Influence Progression of Autoimmunity in Relatives of T1D Patients

Diabetes/Metabolism Research and Reviews, Volume 42, Issue 3, March 2026.
ABSTRACT Aim The genetic loci, ERBB2/IKZF3/GSDMB/ORMDL3 on chromosome 17q, and ERBB3/IKZF4 on chromosome 12q represent confirmed non‐HLA risk factors for the development of autoimmunity and progression to type 1 diabetes (T1D). It is unknown whether both regions can interact to influence the progression of T1D.
Ina M. Mertens, Bart Keymeulen, Frans K. Gorus, Mark Van De Casteele, the Belgian Diabetes Registry   +4 more
wiley   +1 more source

The Roles of Neuregulin-1 in Cardiac Development, Homeostasis, and Disease

Biomarker Insights, 2015
Neuregulin-1 (NRG-1) and its signaling receptors, erythroblastic leukemia viral oncogene homologs (ErbB) 2, 3, and 4, have been implicated in both cardiomyocyte development and disease, as well as in homeostatic cardiac function.
Cassady E. Rupert, Kareen L.K. Coulombe
doaj   +1 more source

Companion Diagnostics in Clinical Therapy: Current Applications and Future Directions

MedComm, Volume 7, Issue 3, March 2026.
Companion diagnostics use biomarker‐based assays to stratify patients for precision therapies, improving outcomes while reducing ineffective treatment and side effects. This review summarizes the evolution, regulatory landscape, clinical applications, and technological platforms of CDx, highlighting their role in biomarker‐driven precision therapy.
Yuesong Wu, Rou Xue, Xiangwen Luo, Jiangnan Liao, Zongbo Zhang, Jinhai Deng, Teng Liu, Xin Li, Zhe‐Sheng Chen, Mingzhu Yin   +9 more
wiley   +1 more source

Input–output behavior of ErbB signaling pathways as revealed by a mass action model trained against dynamic data

Molecular Systems Biology, 2009
The ErbB signaling pathways, which regulate diverse physiological responses such as cell survival, proliferation and motility, have been subjected to extensive molecular analysis.
William W Chen, Birgit Schoeberl, Paul J Jasper, Mario Niepel, Ulrik B Nielsen, Douglas A Lauffenburger, Peter K Sorger   +6 more
doaj   +1 more source

Chromatin Accessibility in Cancer: Biological Functions, Mechanisms, Therapeutic Potential, and Future Directions

MedComm, Volume 7, Issue 3, March 2026.
Cancer remains the leading cause of mortality worldwide, and drug resistance further underscores the urgent need for innovative therapeutic strategies. Chromatin, a stable yet highly dynamic nucleoprotein complex, serves as the primary carrier of genetic material in eukaryotic cells.
Wentao Xia, Min Jiang, Yefei Huang, Kun Ding, Yansu Chen   +4 more
wiley   +1 more source

ErbB signaling in brain injury regeneration: Pathway interactions and therapeutic potential

Neural Regeneration Research
The ErbB signaling network has recently emerged as a key modulator of central nervous system responses to injury. This review provides a comprehensive overview of ErbB receptors and their ligands, highlighting canonical and non-canonical signaling ...
Patricia Pérez-García, Nora Martínez-Gómez, Sonia Vázquez-de Górgolas, Andrea Chamorro-Francisco, Ricardo Pardillo-Díaz, Pedro Nunez-Abades, Carmen Castro, Livia Carrascal   +7 more
doaj   +1 more source